FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to obtaining multi- antigen DNA constructs, expression vectors, containing said constructs, and pharmaceutical compositions, that can be used in medicine. Multi- antigen DNA constructs are obtained for expression of the immunogenic polypeptides of prostate-specific antigens PSA, PSCA, PSMA, that is used in a composition for inhibiting the abnormal cell proliferation or inducing an immune response against prostate-associated antigen in mammals.
EFFECT: invention allows with high efficiency to treat prostate cancer in humans.
24 cl, 43 dwg, 33 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS | 2014 |
|
RU2650860C2 |
| ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
| USING MVA (MODIFIED VACCINIA ANKARA) FOR TREATING PROSTATE CANCER | 2008 |
|
RU2499606C2 |
| ANTI-CANCER VACCINES TARGETING PRAME AND THEIR APPLICATIONS | 2018 |
|
RU2748903C1 |
| ANTICANCER VACCINES TARGETING BORIS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2759681C1 |
| BORIS-TARGETED ANTI-CANCER VACCINES AND METHODS FOR APPLICATION THEREOF | 2018 |
|
RU2799786C2 |
| MESOTHELINE-TARGETED CANCER VACCINES AND THEIR APPLICATION | 2018 |
|
RU2751252C1 |
| MESOTHELIN-TARGETED CANCER VACCINES AND THEIR APPLICATIONS | 2018 |
|
RU2830879C2 |
| FUSED PROTEINS WITH IMMUNOGLOBULIN FC-FRAGMENT FOR ENHANCING IMMUNOGENICITY OF PROTEIN AND PEPTIDE ANTIGENS | 2000 |
|
RU2248214C2 |
